| Literature DB >> 34870681 |
Gary Rance1, Julien Zanin1, Alice Maier2, Donella Chisari1, Kristina M Haebich2,3, Kathryn N North2,3, Gabriel Dabscheck2,4, Marc L Seal2,3, Martin B Delatycki2,3,5, Jonathan M Payne2,3,4.
Abstract
Importance: Neurofibromatosis type 1 (NF1) affects hearing through disruption of central auditory processing. The mechanisms, functional severity, and management implications are unclear. Objective: To investigate auditory neural dysfunction and its perceptual consequences in individuals with NF1. Design, Setting, and Participants: This case-control study included children and adults with NF1 and control participants matched on age, sex, and hearing level. Patients were recruited through specialist neurofibromatosis and neurogenetic outpatient clinics between April and September 2019. An evaluation of auditory neural activity, monaural/binaural processing, and functional hearing was conducted. Diffusion-weighted magnetic resonance imaging (MRI) data were collected from a subset of participants (10 children with NF1 and 10 matched control participants) and evaluated using a fixel-based analysis of apparent fiber density. Main Outcomes and Measures: Type and severity of auditory dysfunction evaluated via laboratory testing and questionnaire data.Entities:
Mesh:
Year: 2021 PMID: 34870681 PMCID: PMC8649832 DOI: 10.1001/jamanetworkopen.2021.36842
Source DB: PubMed Journal: JAMA Netw Open ISSN: 2574-3805
Participant Demographic Characteristics
| Group | No. | Female participants, No. (%) | Male participants, No. (%) | Mean (SD) [range] | |
|---|---|---|---|---|---|
| Age, y | Hearing level, dBHL | ||||
| Audiologic study | |||||
| NF1 | 44 | 18 (41) | 26 (59) | 16.9 (10.7) [6 to 56] | 15.5 (5.8) [0.0 to 38.7] |
| Control | 44 | 18 (41) | 26 (59) | 17.2 (10.2) [6 to 53] | 13.2 (5.7) [−2.5 to 40.0] |
| MRI substudy | |||||
| NF1 | 10 | 8 (80) | 2 (20) | 11.5 (2.1) [9 to 15] | 13.9 (3.3) [8.8 to 16.3] |
| Control | 10 | 8 (80) | 2 (20) | 12.4 (2.1) [8 to 15] | 13.4 (2.3) [10 to 14.4] |
Abbreviations: dBHL, dB hearing level; MRI, magnetic resonance imaging; NF1, neurofibromatosis type 1.
Figure 1. Average Auditory Brainstem Response Waveforms for Neurofibromatosis 1 (NF1) and Control Cohorts
A, The bottom tracings show present cochlear microphonic responses and absent auditory neural potentials for participant 39 in the NF1 cohort. (The cochlear microphonic is a scalp-recorded electrical potential generated by the polarization and depolarization of cochlear hair cells.) B and C, Auditory brainstem responses for a participant with NF1 (B) and her matched control participant (C) to acoustic click stimuli at presentation rates ranging from 8 Hz to 100 Hz.
aPositive peaks in the cochlear microphonic waveform.
Auditory Brainstem Response, Perception, and Self-reported Hearing Disability Findings for Participants With NF1 and Matched Control Participants
| Outcome | Mean (SD) | 95% CI for paired difference | ||||
|---|---|---|---|---|---|---|
| Participants with NF1 | Control participants | Difference | Unadjusted | Adjusted | ||
|
| ||||||
| Wave I latency, ms | 1.50 (0.12) | 1.45 (0.13) | 0.05 (0.17) | −0.00 to 0.10 | .06 | .08 |
| Wave III latency, ms | 3.75 (0.17) | 3.64 (0.15) | 0.11 (0.21) | 0.05 to 0.18 | .001 | .004 |
| Wave V latency, ms | 5.77 (0.31) | 5.41 (0.16) | 0.36 (0.35) | 0.25 to 0.47 | <.001 | <.001 |
| I-III Interpeak latency, ms | 2.27 (0.20) | 2.19 (0.16) | 0.07 (0.27) | −0.00 to 0.16 | .07 | .06 |
| III-V Interpeak latency, ms | 2.02 (0.26) | 1.78 (0.13) | 0.24 (0.29) | 0.16 to 0.33 | <.001 | <.001 |
| Wave I amplitude, μV | 0.34 (0.12) | 0.36 (0.12) | −0.02 (0.14) | −0.09 to 0.04 | .44 | .32 |
| Wave V amplitude, μV | 0.59 (0.23) | 0.69 (0.22) | −0.11 (0.31) | −0.20 to −0.01 | .03 | .02 |
| Maximum rate, Hz | 81.7 (26.5) | 98.9 (5.3) | −17.1 (26.9) | −25.3 to −9.0 | <.001 | <.001 |
|
| ||||||
| 10-Hz AM, dB | −16.3 (4.9) | −18.1 (3.8) | 1.7 (6.0) | −0.17 to 3.64 | .07 | .16 |
| 150-HZ AM, dB | −13.8 (5.6) | −17.1 (2.5) | 3.4 (6.1) | 1.33 to 5.37 | .002 | .004 |
|
| ||||||
| DV90, dB | −13.2 (3.8) | −15.8 (2.8) | 2.6 (4.0) | 1.40 to 3.82 | <.001 | .002 |
| SV90, dB | −11.5 (3.9) | −14.1 (2.9) | 2.6 (3.9) | 1.42 to 3.82 | <.001 | .002 |
| DV0, dB | −5.0 (3.4) | −5.9 (2.5) | 0.9 (3.9) | −0.27 to 2.09 | .15 | .18 |
| SV0, dB | −1.1 (1.9) | −1.3 (1.7) | 0.2 (2.2) | −0.46 to 0.86 | .89 | .69 |
|
| ||||||
| Speech | 7.3 (1.6) | 8.3 (0.9) | −1.0 (1.8) | −1.61 to −0.47 | <.001 | <.001 |
| Spatial | 6.8 (2.2) | 8.0 (1.4) | −1.1 (2.7) | −2.00 to −0.28 | .01 | .009 |
| Quality | 8.1 (1.6) | 8.4 (1.1) | −0.2 (2.1) | −0.91 to 0.44 | .49 | .37 |
Abbreviations: AM, amplitude modulation; DV0, different voice, same direction; DV90, different voice separated by 90°; NF1, neurofibromatosis type 1; SV0, same voice, same direction; SV90, same voice separated by 90°.
Adjusted for age and hearing level.
Maximum rate is the highest stimulus presentation rate (in hertz) at which an auditory brainstem response could be identified.
Hearing disability ratings are based on a 10-point rating scale.
Pairwise Pearson r Correlations Showing the Associations Between Selected Auditory Measures
| Measure 1 | Measure 2 | Correlation (95% CI) | |
|---|---|---|---|
| ABR III-V | AM 150Hz | 0.316 (0.10 to 0.50) | .004 |
| ABR III-V | DV90 | 0.317 (0.11 to 0.49) | .003 |
| ABR III-V | SSQ Speech | −0.229 (−0.42 to −0.01) | .04 |
| AM 150Hz | DV90 | 0.369 (0.16 to 0.54) | .001 |
| AM 150Hz | SSQ Speech | −0.101 (−0.32 to 0.13) | .38 |
| DV90 | SSQ Speech | −0.231 (−0.42 to −0.02) | .03 |
Abbreviations: ABR, auditory brainstem responses; AM, amplitude modulation; DV90, different voices spatially separated by 90°; SSQ, Speech, Spatial, and Qualities of Hearing Scale.
Figure 2. Fixel-Based Analysis Results
A, Coronal slice of the population template diffusion-weighted magnetic resonance imaging (MRI) data, with the box indicating the brainstem where the analysis was performed. B, Magnified brainstem region showing the auditory brainstem pathways (generated using probabilistic tractography)[22] in which apparent fiber density was compared between the neurofibromatosis type 1 (NF1) group and control group.[21] The different colors of the tracts in this image correspond to tract orientation and adhere to the directionally encoded color convention: anterior-posterior is green, superior-inferior is blue, and left-right is red. C, Magnified brainstem region showing the regions of the auditory brainstem pathways in the NF1 group that exhibited significantly lower apparent fiber density (ie, presence of neural degeneration) compared with the control group. This image shows the auditory pathways as fixels (individual fiber populations in a voxel), which are color-coded based on familywise error (FWE)–corrected P values. D, Quantification of the apparent fiber density results in the regions identified as being significant in the fixel-based analysis (C). Values are represented in arbitrary units (AUs). These boxplots present the median (center line), the interquartile range (shaded area of the box), and whiskers (range) of the data.
aP < .001.